Pfizer says no new serious adverse events in DMD gene therapy trial

FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly/File Photo

NEW YORK (Reuters) - Drugmaker Pfizer Inc said on Tuesday that it had administered doses of its experimental gene therapy for rare degenerative muscular condition Duchenne muscular dystrophy (DMD) to an additional 9 boys, with no serious adverse events observed.

The company plans to start a pivotal trial on the gene therapy in ambulatory patients in the next several weeks, Seng Cheng, chief scientific officer of Pfizer’s rare disease unit said during a presentation to investors. The company modified the regimen for the drug earlier this year after three patients had to be hospitalized.

Reporting by Michael Erman, Editing by Franklin Paul